EN DE
Watch IRLAB Therapeutics AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

IRLAB Therapeutics AB (publ) (IRLAB-A) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of IRLAB Therapeutics AB (publ) stock SEK 1.80, price SEK 2.25, that is 19.8% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0012675361

IT IRLAB Therapeutics AB (publ) logo Thin data Nov 10, 2026

IRLAB Therapeutics AB (publ)

IRLAB-A · ST
Expensive, weak quality

Our calculation puts a fair price 20% below what the stock costs today.

Low debt
Revenue last quarter 67% below a year ago.
Fair value kr 1.80 · Overvalued
Quality 26/100
Weak Growth (revenue 3y −2.0 %/yr in SEK)
Loss-making · -67.9% net margin (TTM)
Negative free cash flow
Trails peers (3/8)
Narrow moat 12/100
Thin data
Estimate
Watch IRLAB Therapeutics AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 61.90 kr 1.20 Fair Value kr 1.80 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 1.20 – kr 61.90 · fair‑value band kr 1.35 – kr 2.25 · the kr 2.25 price screens above the kr 1.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow IRLAB Therapeutics AB (publ) in your weekly email

Every Wednesday you see whether IRLAB Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States.

Show moreShow less

The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders.

It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms.

IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.

Stock analysis

IRLAB Therapeutics AB (publ) (IRLAB-A) currently trades at kr 2.25, while our estimate is kr 1.80, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 1.35 (bear) to kr 2.25 (bull), the price of kr 2.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

IRLAB Therapeutics AB (publ) reported revenue of 57.5M SEK in FY2025 versus 208M SEK in FY2021, a compound −27.5%/yr. Reported net income was −110M SEK in FY2025.

Key figures

Market cap 339M SEK (≈ $34.3M) Micro · P/S ratio 3.97 · EPS (TTM) kr −0.6200 · Net margin −67.9% · Return on equity −155% · Return on assets (EBIT) −49.6% (5-year average) · Operating margin −261% · Revenue (TTM) 79.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 87% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, IRLAB-A screens richer than that median.

Fair Value

Bear kr 1.35 Fair Value kr 1.80 Bull kr 2.25
Price kr 2.25 · Downside -19.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 59
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 57
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−39.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+186.1%
Start year 2020 (pandemic). Over 10 years: +34.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−30,486.0% (2020) → −160.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IRLAB-A screens overvalued: fair value 20% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare IRLAB Therapeutics AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −19.8% · Above median
Profitability
Return on assets −79.6% · Bottom 25%
Net margin (12 months) −67.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −67.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 11.02× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 4.27× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs IRLAB-A
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs IRLAB-A
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs IRLAB-A
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs IRLAB-A
argenx SE ARGX $971.55 $908.40 −7% vs IRLAB-A
CSL Limited CSL A$201.68 A$181.40 −10% vs IRLAB-A
Moderna, Inc MRNA $250.83 $158.70 −37% vs IRLAB-A
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs IRLAB-A
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs IRLAB-A
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs IRLAB-A

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IRLAB Therapeutics AB (publ): fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "IRLAB Therapeutics AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/IRLAB-A

Frequently asked questions

Is IRLAB Therapeutics AB (publ) (IRLAB-A) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 1.80 versus a price of kr 2.25, about 20% lower (overvalued).
What is the fair value of IRLAB-A?
Our estimate for IRLAB Therapeutics AB (publ) is kr 1.80 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 2.25.
What is the quality score of IRLAB-A?
IRLAB Therapeutics AB (publ) has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IRLAB Therapeutics AB (publ) (IRLAB-A)?
Our calculated price target is the estimate of kr 1.80 (as of Nov 10, 2026). Cautious scenario kr 1.35, optimistic scenario kr 2.25. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the IRLAB Therapeutics AB (publ) stock forecast for 2026?
Our estimate puts fair value at kr 1.80, about 20% lower versus a price of kr 2.25 (overvalued). Cautious scenario kr 1.35, optimistic scenario kr 2.25. The calculation is refreshed regularly with new filings.
What is the revenue of IRLAB Therapeutics AB (publ) (IRLAB-A)?
IRLAB Therapeutics AB (publ) reported trailing-twelve-month revenue of about 79.3M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of IRLAB Therapeutics AB (publ) (IRLAB-A)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IRLAB Therapeutics AB (publ) it is kr 1.80 per share (as of Nov 10, 2026), against a price of kr 2.25.
Is IRLAB Therapeutics AB (publ) stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IRLAB-A trades above its calculated fair value: price kr 2.25, fair value kr 1.80, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRLAB-A?
No. The price is what the market pays today (kr 2.25); the fair value is what the company's own numbers justify (kr 1.80). For IRLAB Therapeutics AB (publ) the two are kr 0.4450 per share apart. That gap is exactly why we show both numbers side by side.
How much is IRLAB Therapeutics AB (publ) worth?
The market values IRLAB Therapeutics AB (publ) at about 339M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 2.25; our models calculate a fair value of kr 1.80 per share.
What do the bullish and bearish scenarios say about IRLAB-A?
Our models span a range for IRLAB Therapeutics AB (publ): cautious scenario kr 1.35, base kr 1.80, optimistic kr 2.25 per share (as of Nov 10, 2026, price kr 2.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IRLAB Therapeutics AB (publ) (IRLAB-A)?
Balance-sheet figures for IRLAB Therapeutics AB (publ) (as of Nov 10, 2026): return on equity −155.1%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is IRLAB-A from its 52-week high?
IRLAB Therapeutics AB (publ) trades at kr 2.25, about 6% below its 52-week high of kr 2.39 and 87% above the low of kr 1.20 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.80 is for.
Which stocks are comparable to IRLAB Therapeutics AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IRLAB Therapeutics AB (publ) stock attractive at the current price?
The data as of Nov 10, 2026: price kr 2.25, calculated fair value kr 1.80 (−20%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. IRLAB Therapeutics AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The closing price on Nov 10, 2026 was kr 2.25. Our estimate is kr 1.80, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IRLAB Therapeutics AB (publ) right now?
Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of IRLAB Therapeutics AB (publ)

How large is the market capitalisation of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The market capitalisation of IRLAB Therapeutics AB (publ) is 339M SEK (≈ $34.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The price-to-sales ratio of IRLAB Therapeutics AB (publ) is 3.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IRLAB Therapeutics AB (publ) (IRLAB-A)?
Earnings per share at IRLAB Therapeutics AB (publ) are kr −0.6200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The net margin of IRLAB Therapeutics AB (publ) is −67.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The return on equity (ROE) of IRLAB Therapeutics AB (publ) is −155% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IRLAB Therapeutics AB (publ) (IRLAB-A)?
On an EBIT basis the return on assets of IRLAB Therapeutics AB (publ) is −49.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IRLAB Therapeutics AB (publ) (IRLAB-A)?
The operating margin of IRLAB Therapeutics AB (publ) is −261% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IRLAB Therapeutics AB (publ) (IRLAB-A)?
Revenue at IRLAB Therapeutics AB (publ) is growing −67.2% versus a year earlier (3y avg −2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does IRLAB Therapeutics AB (publ) (IRLAB-A) generate?
The free cash flow of IRLAB Therapeutics AB (publ) is −55.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does IRLAB Therapeutics AB (publ) (IRLAB-A) hold?
IRLAB Therapeutics AB (publ) holds more cash than debt, 51.9M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch IRLAB Therapeutics AB (publ) in the live analysis

One click puts IRLAB Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.